Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance [Yahoo! Finance]
Windtree Therapeutics, Inc. (WINT)
Last windtree therapeutics, inc. earnings: 8/21 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
windtreetx.investorroom.com
Company Research
Source: Yahoo! Finance
MONMOUTH JUNCTION, N.J., February 07, 2024 BUSINESS WIRE )--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Michael Magee as vice president, quality and compliance. "Michael joins Tris Pharma at an incredibly exciting time in which we have an established portfolio of ADHD medications and a diverse pipeline of late-stage assets, and where his proven track record in the pharmaceutical industry will play a key role in further enhancing our ongoing quality assurance and compliance initiatives," said Ketan Mehta, founder and CEO at Tris Pharma. "With Michael on board, we are well-positioned to navigate our growth and continue delivering on our mission to optimize patient outcomes through differentiated therapeutic approaches." Mr. Magee will lead and further strengthen Tris Pharma's continued development and management of qua
Show less
Read more
Impact Snapshot
Event Time:
WINT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WINT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WINT alerts
High impacting Windtree Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
WINT
News
- Windtree Therapeutics Announces Reverse Stock SplitGlobeNewswire
- Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates [Yahoo! Finance]Yahoo! Finance
- Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesGlobeNewswire
- Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing [Yahoo! Finance]Yahoo! Finance
- Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingGlobeNewswire
WINT
Sec Filings
- 4/23/24 - Form 8-K
- 4/17/24 - Form S-3/A
- 4/17/24 - Form 8-K
- WINT's page on the SEC website